Pharsight

1. List of Xifaxan drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7612199	SALIX PHARMS	Polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 4 months from now)
US8158781	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 4 months from now)
US8835452	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 4 months from now)
US7045620	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations	Jun, 2024 (1 year, 4 months from now)
US7902206	SALIX PHARMS	Polymorphic forms α, β and γ of rifaximin	Jun, 2024 (1 year, 4 months from now)
US7906542	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2025 (2 years from now)
US8741904	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (3 years from now)
US8193196	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Sep, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158644	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 4 months from now)
US8853231	SALIX PHARMS	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin	Jun, 2024 (1 year, 4 months from now)
US7915275	SALIX PHARMS	Use of polymorphic forms of rifaximin for medical preparations	Feb, 2025 (2 years from now)
US8518949	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (3 years from now)
US9271968	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (3 years from now)
US10703763	SALIX PHARMS	Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations	Feb, 2026 (3 years from now)
US10456384	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (6 years from now)
US10765667	SALIX PHARMS	Methods for treating irritable bowel syndrome (IBS)	Feb, 2029 (6 years from now)
US8309569	SALIX PHARMS	Methods for treating diarrhea-associated irritable bowel syndrome	Jul, 2029 (6 years from now)
US10335397	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (6 years from now)
US8946252	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (6 years from now)
US9421195	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (6 years from now)
US7928115	SALIX PHARMS	Methods of treating travelers diarrhea and hepatic encephalopathy	Jul, 2029 (6 years from now)
US10709694	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (6 years from now)
US9629828	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (6 years from now)
US8829017	SALIX PHARMS	Methods of treating traveler's diarrhea and hepatic encephalopathy	Jul, 2029 (6 years from now)
US10314828	SALIX PHARMS	Methods of treating hepatic encephalopathy	Jul, 2029 (6 years from now)
US8642573	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (6 years from now)
US8969398	SALIX PHARMS	Methods of treating hepatic encephalopathy	Oct, 2029 (6 years from now)

Market Authorisation Date: 25 May, 2004

Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; Reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; Reduction in risk of overt hepatic encephalopathy (he) recurrence; Method of treating travelers' diarrhea; Reduction in risk of overt hepatic encephalopathy (he) in adults; Treatment of patients with hepatic encephalopathy (he); The treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence

Dosage: TABLET;ORAL